ASH 2011

Combining the hyperCVAD regimen with dasatinib, a dual Scr and BCR-ABL kinase inhibitor, is effective in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia in the lymphoid blast phase (CML-LB), according to investigators at the 53rd American Society of Hematology Annual Meeting and Exposition.

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented evidence demonstrating promising survival rates in Burkitt’s lymphoma (BL) when rituximab was added to the CODOX-M and IVAC chemotherapy regimens and when liposomal doxorubicin was used in place of doxorubicin in the CODOX-M regimen.

Rami S. Komrokji, MD, from H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL, and colleagues reported study data indicating that the CLAG regimen (cladribine, cytarabine, granulocyte colony stimulating factor) in combination with imatinib mesylate showed encouraging signs of activity in relapsed or refractory (RR) acute myeloid leukemia (AML). Results of this single-institution, two-stage, Phase 2 study were presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

The rituximab, bendamustine and cytarabine (R-BAC) chemotherapy regimen was shown to be effective in previously untreated patients >65 years old with mantle cell lymphoma (MCL), as well as in patients who are relapsed or refractory (R/R) to one previous line of immunochemotherapy, based on results of a prospective Phase 2 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data showing that bafetinib has therapeutic potential in the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) who relapsed or were refractory to >1 course of treatment with either an alkylating agent, rituximab, or a fludarabine-based regimen.

In children with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS), no significant differences in efficacy or toxicity were observed between idarubicin and mitoxantrone induction and first intensification courses, results of a randomized, Phase 3 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found.

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data from the SAPHIRE trial demonstrating that resminostat, an oral pan-histone deacetylase (HDAC) inhibitor, showed considerable anti-tumor activity in a heavily pre-treated population with Hodgkin’s Lymphoma.

Long-term use of romiplostim in myelodysplastic syndrome (MDS) patients for up to 3.5 years (five years including therapy on prior studies) produced platelet responses in 83% of patients, according to an open-label extension study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

Standard-dose rituximab plus multiple courses of pulse dexamethasone was shown to be active with manageable toxicity in patients with immune thrombocytopenia (ITP), according to results of a retrospective analysis presented during the 53rd American Society of Hematology Annual Meeting and Exposition.

A retrospective review reported on during the 53rd American Society of Hematology Annual Meeting and Exposition found vinorelbine, paclitaxel, etoposide, cisplatin and cytarabine (VTEPA) to be a promising salvage regimen in patients with relapsed/refractory Hodgkin’s lymphoma. However, patients with refractory diffuse large B-cell lymphoma (DLBCL) had “exceedingly poor” outcomes in comparison.